NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Dynavax Technologies Corporation ("Dynavax" or the "Company") (Nasdaq:DVAX) of the August 19, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain executives.
A complaint has been filed on behalf of all persons who purchased Dynavax securities between April 26, 2012 and June 10, 2013 (the "Class Period").
The complaint alleges that Dynavax made materially false and misleading statements regarding the viability of HEPLISAV, the Company's lead product candidate. Specifically, the complaint alleges that Dynavax failed to disclose: (i) that the clinical trial for HEPLISAV was flawed in that it was not representative of the United States population and did not provide information regarding concurrent use of HEPLISAV with other vaccines; and (ii) the Company did not provide the Food and Drug Administration ("FDA") with adequate information regarding HEPLISAV manufacturing processes and controls.
On June 10, 2013, Dynavax issued a press release announcing that the FDA would require additional safety trials prior to granting approval of HEPLISAV. Following this news, Dynavax's stock price dropped $1.07 or 43%.
Request more information now by clicking here: www.faruqilaw.com/DVAX. There is no cost or obligation to you.
If you invested in Dynavax stock or options between April 26, 2012 and June 10, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/DVAX. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Dynavax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
CONTACT: FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. firstname.lastname@example.org Francis McConville, Esq. email@example.com Telephone: (877) 247-4292 or (212) 983-9330Source:Faruqi & Faruqi LLP